Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023
Oxytocin effects on amygdala reactivity to angry faces in males and females with antisocial personality disorder.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Intranasal oxytocin modulates brain activity during emotional processing in children with treatment resistant conduct problems.Scientific reports · 2025Trial
- Emotion-specific amygdala habituation in treatment-referred young adults with antisocial histories: links with internalizing and externalizing symptoms and future recidivism.Neuroimage. Reports · 2026Article
- Blame through my eyes: How first-person perspective shapes social attention and attribution in harmful interactions - a comparative eye tracking study.Borderline personality disorder and emotion dysregulation · 2026Article
- Resting-state brain function and its modulation by intranasal oxytocin in antisocial personality disorder with and without psychopathy.Scientific reports · 2026Article
- The Promise of Intranasal Oxytocin in Treating Borderline Personality Disorder: A Narrative Review.Brain sciences · 2025Review
- Why Do They Do It? The Psychology Behind Antisocial Behavior in Children and Adolescents.Pediatric reports · 2025Review
- Psychophysiology of facial emotion recognition in psychopathy dimensions and oxytocin's role: A scoping review.PloS one · 2025Article
- Review
- Is Oxytocin a Contributor to Behavioral and Metabolic Features in Prader-Willi Syndrome?Current issues in molecular biology · 2024Review
- Exploring the influence of stress on aggressive behavior and sexual function: Role of neuromodulator pathways and epigenetics.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The amygdala is a key region in current neurocircuitry models of reactive aggression as it is crucially involved in detecting social threat and provocation. An increased amygdala reactivity to angry faces has been reported in aggression-prone individuals and the neuropeptide oxytocin (OT) could dampen anger-related amygdala reactivity in a number of mental disorders. One example is the antisocial personality disorder (ASPD) which has so far only been studied in limited numbers. To address the question whether OT can normalize amygdala hyperreactivity to emotional faces, we conducted a functional magnetic resonance imaging experiment with 20 men and 18 women with ASPD and 20 male and 20 female healthy control (HC) participants in a double-blind, randomized, placebo (PLC)-controlled within-subject design. Participants were exposed to an emotion classification task (fearful, angry, and happy faces) after receiving an intranasal dose (24 IU) of synthetic OT or PLC. We found OT to attenuate right amygdala hyperactivity to angry faces in participants with ASPD to such an extent that the intensity of amygdala activity in the ASPD group in the OT condition decreased to the level of amygdala activity in the PLC condition in the HC group. There was also a trend that OT effects were generally larger in women than in men. These findings suggest that OT differentially modulates the amygdala following social threatening or provoking cues in dependence of psychopathology (ASPD vs. HC) and sex (male vs. female). Particularly female ASPD patients could benefit from OT in the treatment of reactive aggression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.